Clinical and pharmacologic effects of combinations of 6-thioguanine and duazomycin A in patients with neoplastic disease.
D000328:Adult; D000368:Aged; D000963:Antimetabolites / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004357:Drug Synergism; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008441:Maxillary Neoplasms / Q000188:drug therapy; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D010610:Pharyngeal Neoplasms / Q000188:drug therapy; D013460:Sulfur Isotopes; D013866:Thioguanine / Q000378:metabolism / Q000627:therapeutic use*; D014062:Tongue Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D000963:Antimetabolites; D001391:Azo Compounds; D013460:Sulfur Isotopes; D013866:Thioguanine